As Sergey Lavrov and his Russian diplomatic team took their seats at a table opposite Secretary of State Rex Tillerson and the American delegation, Mitchell can be heard yelling a question over his back.
Mitchell, 70, the network's chief foreign affairs correspondent, however did not receive the answer she wanted.
"Mr. Lavrov," Mitchell, began, asking the diplomat about Syria. "The Russians don't believe the [U.S.] intelligence."
"Who was bringing you up [as a child]?" Lavrov boomed, cutting her off.
"Who was giving you your manners, you know?" he asked, sounding annoyed.
Lavrov, 67, then turned his attention back to the table and began conversing with them in Russian.
Spotlight on PSA Trailblazers It's 2026, and Infotech has dropped its latest bombshell—the Professional Services Automation Data Quadrant Report. This ain't just your run-of-the-mill software rankings; it's a peek into tools that could make or break project management for service-oriented businesses. Five top dogs, RocketLane, Wrike, Accelo, SAP Professional Services...
Breaking Ground: NORROY's Radiopharmaceutical Innovations If you thought the radiopharmaceutical game was stuck in the same ol' rut, NORROY Bioscience just flipped the script. Standing out at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM'26) in Vienna, they trotted out enough breakthroughs to make you wonder if they're secretly running on...
AlphaESS: Consistency Breeds Success Can't ignore a company that keeps hitting the marks quarter after quarter, kid. AlphaESS just bagged its fifth consecutive Tier 1 status from BloombergNEF for Q4 2026—that's no joke in the buzzing world of energy storage. What makes this outfit tick? It's not just sticking to the same old script; they keep leveling up while everyone...
Cracking Open GomSpace's Q3 Gains You don't just stumble upon profitability in this market; that's for sure. GomSpace, however, seems to have a knack for finding its stride amidst the chaos. In their latest earnings report, it looks like they're not just coasting—they're powering through with profitable growth in the third quarter. Who would have thought? These folks...
Midterms and 'Trump Derangement Syndrome': What's the Deal? Every election season there's something new to raise eyebrows, and this time it's 'Trump Derangement Syndrome' (TDS) taking the spotlight. After the dust of the 2026 mid-terms started settling, it turns out there's more than just traditional candidate bickering shaping votes. Can you guess what's driving voters?...
KT&G Climbs to New Heights with Record-Setting Q3 If you're eyeballing the markets like a hawk, KT&G (KRX: 033780) just gave you something to squawk about. In the world of stocks, milestones are few and far between, but KT&G is handing out milestones like candy in Q3. They rolled out their numbers for the quarter, and let me tell ya, this was no pie-in-the-sky nonsense....
SKF's Green Initiative: A Major Step Forward You ever find yourself in a room full of big players, each trying to outdo the other? That's the stage set for SKF at COP31, where they're not just strutting around showing off but actually offering some substance—a rarity in these highbrow gatherings. They're juicing up the talk around energy efficiency and circularity...
Elderly Residents at Risk After Data Breach Well, here we go again — another day, another data breach debacle. This time, it's Magnolia Management putting senior residents' sensitive information on a silver platter for potential cyber intruders. We're talking names, Social Security numbers, and medical records — the whole shebang. When you're handling such crucial...
Vaccination Confusion: Could Clarity Finally Be Here? Here's the scoop, folks. In the swirling mess of immunization advice, a coalition of top medical societies has thrown a lifeline to clinicians. If you're drowning in conflicting vaccine guidance, this panel's unified stance might just be your life raft. The Coalition Forces of Immunization We have the Vaccine Guidance...
So, Marelli's rolling out the heavy artillery with the appointment of Bram Schot as their future Chair. This isn't just reshuffling a few chairs on the deck of a wobbly ship. No, Marelli's emergence from Chapter 11, with Schot at the helm, is more akin to a full-blown course correction. The man comes seasoned, having braved the corporate gales at Audi, Mercedes-Benz, and...
Boldyn Networks Achieves Major Recognition in Private 5G Sector Boldyn Networks, a global leader in private networks and shared communications infrastructure, has made waves in the telecommunications industry with its recent recognition as a Major Player in the IDC MarketScape: European Enterprise Private 5G Solutions 2025 Vendor Assessment. This validation reflects...
LinkSquares: A Game Changer for Contract Management In the world of legal and business operations, few things eat away at patience—let alone profits—like the cumbersome dance of contract management. Enter LinkSquares, strutting onto the stage with its new all-agentic CLM platform, promising to turn this often painful process into a streamlined operation that saves...
Sanctuary Medicinals Shines at NECANN Cup Boston 2025 Sanctuary Medicinals proudly celebrates a remarkable achievement at the 6th Annual NECANN Cup Boston. The company earned the impressive title of 4th place in the competitive Solvent Concentrates category. This accolade showcases Sanctuary Medicinals' unwavering commitment to excellence, innovation, and quality within...
The Growing Challenge of Obesity Drug Coverage For many individuals battling obesity, the struggle is not just about losing weight. It’s also about bearing the financial burden of treatments. With increasing limitations from insurers regarding weight-loss drugs, patients are often forced to alter their lifestyles significantly. Vacations are postponed, dining out is...
Important Attention for Humacyte, Inc. Investors As an investor in Humacyte, Inc., it’s essential to stay informed about legal opportunities that could impact your investments. The Rosen Law Firm, known for its dedication to protecting investor rights, is reminding those who purchased Humacyte securities during a specified period about an important upcoming deadline....
